Nuvectis Pharma Inc (NVCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $696.03M
Last updated: Nov 17, 2026 at 11:05 AM ET
Nuvectis Pharma Inc (NVCT) Competitors
The companies most similar to Nuvectis Pharma are Nuvation Bio (NUVB), Nektar Therapeutics (NKTR) and Janux Therapeutics (JANX). By market cap, Nuvectis Pharma ranks 7th of the 13 companies on this page; Nuvation Bio (NUVB) is the largest at $1.41B. The median P/E of the 3 companies with a P/E is 39.3x.
Peer Comparison
NVCT's revenue growth of 0.0% is above the peer median of -1.5%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Nuvectis Pharma (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| Nektar Therapeutics (NKTR) | $1.27B | N/A | 23.9x | 0.0% | N/A | -20.4% | 0.00% |
| Janux Therapeutics Inc (JANX) | $695.65M | N/A | 29.6x | 0.0% | N/A | -7.1% | 0.00% |
| Pharming Group NV (PHAR) | $891.80M | 39.3x | 2.4x | 6.3% | 7.9% | 20.8% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Theravance Biopharma Inc (TBPH) | $884.18M | 95.1x | 8.4x | 51.6% | N/A | -20.9% | 0.00% |
| DBV Technologies (DBVT) | $692.19M | N/A | N/A | 0.0% | -130.3% | -42.9% | 0.00% |
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Zevra Therapeutics Inc. (ZVRA) | $540.30M | 11.6x | 3.7x | 52.8% | N/A | 44.9% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Valneva SE ADR (VALN) | $538.42M | N/A | 3.2x | -110.3% | -44.2% | -27.7% | 0.00% |
| Novavax Inc (NVAX) | $1.41B | N/A | 3.2x | -18.6% | -66.6% | -3.0% | 0.00% |
| Peer median | $789.92M | 39.3x | 6.7x | 0.0% | -31.4% | -1.5% | 0.00% |
Similar Companies
These are the 12 companies most similar to Nuvectis Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| Nektar Therapeutics (NKTR) | Nektar Therapeutics is a biopharmaceutical company. | NKTR competitors |
| Janux Therapeutics Inc (JANX) | Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology... | JANX competitors |
| Pharming Group NV (PHAR) | Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States... | PHAR competitors |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Theravance Biopharma Inc (TBPH) | Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe... | |
| DBV Technologies (DBVT) | DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. | DBVT competitors |
| Cullinan Oncology LLC (CGEM) | Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients... | CGEM competitors |
| Zevra Therapeutics Inc. (ZVRA) | Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions... | ZVRA competitors |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. | |
| Valneva SE ADR (VALN) | Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet... | VALN competitors |
| Novavax Inc (NVAX) | Novavax, Inc., a biotechnology company, focuses on the discovery, development and commercialization of vaccines to prevent serious infectious diseases... | NVAX competitors |
Frequently Asked Questions About NVCT
Who are Nuvectis Pharma's main competitors?
The companies most similar to Nuvectis Pharma include Nuvation Bio (NUVB), Nektar Therapeutics (NKTR), Janux Therapeutics (JANX), Pharming Group NV (PHAR) and Corvus Pharmaceuticals (CRVS), listed from the closest match.
Who is Nuvectis Pharma's biggest competitor?
Nuvation Bio (NUVB) is both the largest of the similar companies at $1.41B and the closest match by business profile, size, sector and industry.
How does NVCT stock compare with its competitors?
NVCT's net margin is 0.0% against a peer median of 0.0%.
Which of Nuvectis Pharma's competitors pays a higher dividend?
Nuvectis Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Nuvectis Pharma bigger than its competitors?
No. Nuvectis Pharma is 7th by market cap among the 13 companies on this page; the largest is Nuvation Bio (NUVB) at $1.41B.
NVCT pages: Overview, Earnings, Forecast, Financials, Competitors